IMG_4442.JPG

Epilepsy (Seizure Disorder)

Statistics on Epilepsy:

In 2015 the CDC recorded 1.2% of the US population as having epilepsy. This accounts for 3.4 million people nationwide. Broken down, this translates to roughly 3 million adults, and 470,000 children.

(Source: The Centers for Disease Control CDC, www.cdc.gov/epilepsy/data)

US Patent 9125859, Sep 8, 2015 - Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy

US Patent 9066920, Jun 30, 2015 - Use of one or a combination of phyto-cannabinoid in the treatment of epilepsy

Cannabis and Epilepsy from recreational abuse to therapeutic use

Walley, B.

University of Reading: School of Chemistry, Food Biosciences & Pharmacy. 2007, online presentation.

Activation of the Cannabinoid Type-1 Receptor Mediates the Anti-Convulsant Properties of Cannabinoids in the Hippocampal Neuronal Culture Models of Acquired Epilepsy and Status Epilepticus

Blair, Robert E., et al.

The Journal of Pharmacology and Experimental Therapeutics. 2006 Jun, 317(3): 1072-1078 (Full).

The Endogenous Cannabinoid System Regulates Seizure Frequency and Duration in a Model of Temporal Lobe Epilepsy

Wallace, Melisa J., et al.

The Journal of Pharmacology and Experimental Therapeutics. 2003 Sep, 307(1): 129-137 (Full). 

The influence of Cannabidiol and Δ-9 Tetrahydrocannabinol on Cobalt Epilepsy in Rats

Chiu, Pauline, et al.

Epilepsia: Official Journal of the International League Against Epilepsy. 2007 Nov 5, 20(4): 365-375 (abstract).

Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy 

Porter, Brenda E., et al.

Epilepsy and Behavior. 2013 Dec, 29(3): 574-577 (abstract).

A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol

Russo, Ethan B., et al.

Medical Hypotheses. 2006, 66(2): 234-246 (abstract). 

Biomedical benefits of cannabinoids?

Ashton, C.H., et al.

Addiction Biology. 2006 Jun 9, 4(2): 111-126 (abstract).

The therapeutic potential of cannabis

Baker, David, et al.

The Lancet Neurology. 2003 May, 2(5): 291-298 (abstract).

Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity

Wallace, Melisa J., et al.

European Journal of Pharmacology. 2002 Oct 11, 452(3): 295-301 (abstract). 

Neurobehavioral actions of cannabichromene and interactions with Δ-9 tetrahydrocannabinol

Davis, Marvin W., et al. 

General Pharmacology: The Vascular System. 1983, 14(2): 247-252 (abstract).  

Antiepileptic Potential of Cannabidiol Analogs

Consroe, Dr. P., et al.

The Journal of Clinical Pharmacology. 1981 Aug, 21(S1): 428-436 (abstract). 


The Cannabinoids and Potential Antiepileptics 

Karler, Dr. Ralph, et al.

The Journal of Clinical Pharmacology. 1981 Aug, 21(S1): 437-448 (abstract). 

Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients

Cunha, J.M., et al.

Pharmacology. 1980, 21(3): 175-185 (abstract).

Toward drugs derived from cannabis

Mechoulam, R, et al. 

Naturwissenschaften. 1978 Apr, 65(4): 174-179 (abstract). 

Cannabidiol--antiepileptic drug comparisons and interactions in experimentally induced seizure in rats.

Consroe, P., et al.

The Journal of Psychopharmacology and Experimental Therapeutics. 1977 Apr, 201(1): 26-32 (abstract).

Effect of cannabidiol and of other Cannabis sativa compounds on hippocampal seizure discharges 

Izquierdo, Ivan, et al.

Psychopharmacologia. 1973, 28(1): 95-102 (abstract).